Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Rhea-AI Summary

Tetra Bio-Pharma has filed a PCT patent application for Cannabis Plant Residue (PCT/CA2021/050886), dated June 28, 2021. The application aims to protect its use as a prebiotic supplement alongside a partnership with Thorne HealthTech for FDA GRAS status, which would expand its applications in food and dietary supplements. Research shows that cannabis residue enhances beneficial gut microbes, making it a promising candidate for gastrointestinal health. This development aligns with Tetra's commitment to cannabinoid-based drug discovery and innovation.

Positive

• Filed PCT patent application for Cannabis Plant Residue, enhancing IP protection.
• Research indicates cannabis residue improves beneficial gut microbes.
• Partnership with Thorne HealthTech to pursue FDA GRAS status for broader applications.

Negative

• None.

OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing date of June 28, 2021. Through the Tetra partnership with Thorne HealthTech, a submission to the U.S. Food and Drug Administration for Generally Recognized as Safe (GRAS) is being pursued. GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.

Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including both Lactobaccillus rhamnosus and Bifidobacterium longum. When compared against the industry standard inulin, Tetra's findings suggest this previously considered "waste material" to be discarded after cannabinoid extraction, as an excellent candidate for use as a novel prebiotic supplement.

If granted, this patent application will provide Tetra with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product  or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-files-pct-patent-application-for-cannabis-plant-residue-301343783.html

SOURCE Tetra Bio-Pharma Inc.

FAQ

What is the significance of Tetra Bio-Pharma's PCT patent application filed on June 28, 2021?

The PCT patent application protects the use of cannabis plant residue as a prebiotic supplement, indicating innovation in cannabinoid-based products.

What is the role of Thorne HealthTech in Tetra Bio-Pharma's recent announcement regarding GRAS status?

Thorne HealthTech is collaborating with Tetra Bio-Pharma to pursue FDA GRAS status for the cannabis plant residue, enabling its use in food and dietary supplements.

How does cannabis plant residue benefit gastrointestinal health according to Tetra Bio-Pharma's research?

Research shows that cannabis plant residue enhances the growth of beneficial gut microbes, suggesting its potential as a prebiotic supplement.